AEON Biopharma, Inc.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing botulinum toxin type A-based therapeutics, with lead candidate ABP-450 targeting therapeutic indications. The company pursued its path to public markets through a business combination with Dune Acquisition Corporation, a healthcare-focused special purpose acquisition company that completed its IPO in 2021. On March 3, 2022, AEON filed a Form 10-Q/A — an amended quarterly report — with the SEC under CIK 0001837607 and accession number 0001104659-22-029703, reflecting updates to previously filed financial disclosures during the pre-merger period. The company operates in the biopharmaceutical sector with a neurotoxin therapeutics focus. Sign up at SpacDesk for full filing history, sponsor profiles, and deal-level analytics on AEON Biopharma and the broader SPAC universe.